Gain Therapeutics (GANX) Gains from Sales and Divestitures (2023 - 2025)
Historic Gains from Sales and Divestitures for Gain Therapeutics (GANX) over the last 3 years, with Q3 2025 value amounting to $97952.0.
- Gain Therapeutics' Gains from Sales and Divestitures rose 5851.38% to $97952.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $97952.0, marking a year-over-year increase of 5851.38%. This contributed to the annual value of $61794.0 for FY2024, which is 6402.12% down from last year.
- Per Gain Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $97952.0 for Q3 2025, which was up 5851.38% from $95069.0 recorded in Q2 2025.
- Gain Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $171751.0 during Q4 2023, with a 5-year trough of $31125.0 in Q1 2024.
- Moreover, its 3-year median value for Gains from Sales and Divestitures was $65629.5 (2023), whereas its average is $84608.9.
- Per our database at Business Quant, Gain Therapeutics' Gains from Sales and Divestitures plummeted by 6402.12% in 2024 and then surged by 16420.53% in 2025.
- Over the past 3 years, Gain Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $171751.0 in 2023, then tumbled by 64.02% to $61794.0 in 2024, then skyrocketed by 58.51% to $97952.0 in 2025.
- Its Gains from Sales and Divestitures stands at $97952.0 for Q3 2025, versus $95069.0 for Q2 2025 and $63859.0 for Q1 2025.